Baxter International Inc. stock (US0673431090): Recent 2% price gain on NYSE

Baxter International Inc. stock rose 2.05% to $17.89 on May 12, 2026, amid ongoing trading activity in the medical products sector. Investors track the NYSE-listed healthcare firm for its role in renal care and hospital products.

Baxter International Inc. stock advanced 2.05% on Tuesday, May 12, 2026, closing at $17.89 after rising from $17.53 on the NYSE, stockinvest.us as of May 13, 2026. This move reflects continued interest in the medical device maker, which serves US hospitals and patients with essential therapies.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Baxter International
• Sector/industry: Medical products and healthcare
• Headquarters/country: United States
• Core markets: US, Europe, global hospitals
• Key revenue drivers: Renal care, hospital products
• Home exchange/listing venue: NYSE (BAX)
• Trading currency: USD

Baxter International Inc.: core business model

Baxter International Inc. develops, manufactures and markets healthcare products for hospitals worldwide, with a strong US presence. The company focuses on therapies for chronic kidney failure, sterile IV solutions and infusion systems used in US medical facilities. Its business model relies on recurring demand from dialysis centers and surgical centers across the United States.

Headquartered in Deerfield, Illinois, Baxter operates through segments including Medical Products and Therapies, Kidney Care and Acute Therapies. These divisions generate stable revenue from essential medical supplies, serving over 100 countries but with significant exposure to the US healthcare system.

Main revenue and product drivers for Baxter International Inc.

Renal care products, including peritoneal dialysis solutions, represent a key revenue driver, supporting US patients with home dialysis options. Hospital products like IV fluids and nutritionals also contribute substantially, driven by steady hospital volumes in the US market.

The company's portfolio includes the Sharesource platform for remote patient monitoring, enhancing its position in connected health solutions relevant to US telehealth trends. In July 2025, shares traded at $29.22 after a 1.56% gain from $28.77, stockinvest.us as of Jul 25, 2025, highlighting price volatility amid sector dynamics.

Industry trends and competitive position

The medical products industry faces pressures from supply chain issues and regulatory scrutiny, yet Baxter maintains a competitive edge through its scale in renal care. US investors note its role in addressing chronic disease burdens, with competitors like DaVita and Fresenius Medical Care in the dialysis space.

Why Baxter International Inc. matters for US investors

Baxter's NYSE listing and heavy US revenue exposure make it relevant for American portfolios focused on defensive healthcare. Its products support the aging US population's needs in kidney disease management, a growing market segment.

Conclusion

Baxter International Inc. continues to navigate healthcare demands with its core offerings in renal and hospital products. The recent 2.05% stock gain on May 12, 2026, underscores market interest, while historical levels like $29.22 in July 2025 provide context on fluctuations. US investors monitor its position amid sector trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.